New Surrogate Marker for ADT Evaluation Proposed
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Male Reproductive Cancers
Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
Men With Prostate Cancer Willing to Accept Worse Survival Odds to Improve QoL
Trade-offs should be carefully considered, as data have indicated that many QoL factors eventually even out.
Prognostic Model for Survival in Metastatic Prostate Cancer
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
Anticarcinogenic Activity of Fish Oil Explored in Study
Omega-3 fatty acids found in fish oil act through a host receptor, GPR120, to confer anti-prostate cancer effects. Additional studies are underway.
Radiotherapy Did Not Improve Survival in All Patients With Metastatic Prostate Cancer
Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.
Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
The regimen did not improve survival and increased bone fractures.
Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen deprivation therapy in men with asymptomatic, nonmetastatic CRPC.
Comparison of Multimodal Approaches in High-Risk Prostate Cancer
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
High Mutation Load Seen in the High-Risk Prostate Tumors of African Men
Differences in TMB between African and European patients show that “racial mutational disparity is not a technical or computational artifact,” according to authors.
Next post in Prostate Cancer
